title: Discontinued drug therapies to treat diabetes in 2015.
abstract: This manuscript describes 21 drug targets in the area of diabetes and related conditions that were discontinued in 2015. Areas covered: The material for this paper was obtained by contacting biopharmaceutical companies, reviewing their pipelines, press releases and annual reports. Additionally, the authors searched clinicaltrials.gov, PubMed and general Internet search engines. Majority of the compounds were in early stages of the development. Expert opinion: Business reasons for termination of the drug projects emerge more and more frequently over the years. Safety signals usually appear early in the development and are often associated with novel drugs. 2015 medicines with inadequate efficacy were unable to compete with existing approved members of the class they represented.
authors.affiliation: a Department of Medicine , University of Maryland School of Medicine , Baltimore , MD , USA.
authors.forename: Maka S
authors.initials: MS
authors.lastname: Hedrington
authors.affiliation: a Department of Medicine , University of Maryland School of Medicine , Baltimore , MD , USA.
authors.forename: Stephen N
authors.initials: SN
authors.lastname: Davis
mesh_terms: D000818:Animals; D003920:Diabetes Mellitus / Q000188:drug therapy*; D015195:Drug Design; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D015507:Drugs, Investigational; D007004:Hypoglycemic Agents
keywords: Peglispro; diabetes; diabetes nephropathy; discontinued drug; insulin